We are really excited to have been awarded £1.1m by the EPSRC to develop injectable implants for the treatment of chronic disease. The other academic members of the team on this project are Andrew Owen, Steve Rannard and Victoria Kearns.
The Innovation to Commercialisation of University Research (ICURe) scheme is in association with Innovate UK and aims to support the commercialisation of research. The funding worth £40k will allow 3 months of full time travel and business engagement.
More details of the scheme can be seen here.
Our work on injectable formulations for ocular drug delivery has received funding worth over £800k from the EPSRC. This work will be conducted with Victoria Kearns and Steve Rannard at the University of Liverpool. A press release on the funding can be seen here.
This year we had the inaugural Christmas meal at Tom’s house. Next year we hope to time it so that more of the group are able to attend.
Congratulations to Mona for passing her PhD viva with minor corrections!
Adam attended the ACS Meeting in Washington to give an oral presentation of the work on his recently published work on nanogel/solid drug nanoparticle composites for sustained drug delivery. Adam’s would like to thank the SCI and RSC for financially supporting with a Rideal Travel Bursary, you can read his report on the conference here.
The Nanomedicine Team at Liverpool was awarded “Partnership of the Year” at the university’s annual staff awards.
Our long standing collaboration with the Nanomedicine Team at Liverpool has resulted in an article recently published in Nature Communications. In this paper, we highly an acceleration approach to the discover of HIV nanomedicines. We used a rapid small-scale screening method to produce large libraries of solid drug nanoparticles targeting oral dose. Through a close integration with pharmacology, we carried out iterative pharmacological and chemical evaluation to establish potential candidates for progression through to clinical manufacture. The wide applicability of our strategy has implications for multiple therapy development programmes.
See here for the full article.